Amendment No. 2 to Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated
SmithKline Beecham Corporation (doing business as GlaxoSmithKline) and Quest Diagnostics Incorporated have agreed to extend the term of their existing Letter of Agreement. The new expiration date is the earlier of June 30, 2008, or when a new Global Clinical Trials Agreement is fully executed. All other terms of the original agreement remain unchanged. This amendment is effective upon signature by both parties' authorized representatives.
Exhibit 10.6
CONFIDENTIAL
Amendment #2 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated
| 1. | The purpose of this Amendment #2 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) June 30, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement. |
| 2. | All other terms and conditions of the LOA shall remain in full force and effect. |
| 3. | The parties hereto agree to this Amendment #2 to the LOA by their authorized signatures below. |
| SMITHKLINE BEECHAM CORPORATION | QUEST DIAGNOSTICS INCORPORATED | ||
| /s/ Paula M. Russella | /s/ Daniel P. Megronigle | ||
| Paula M. Russella | Daniel P. Megronigle | ||
| Sourcing Group Manager | Executive Director, Sales & Marketing | ||
| May 21, 2008 | May 15, 2008 | ||
| Date | Date | ||
